Avoiding the perfect storm: The biologic and clinical case for reevaluating the 7-day expectation for methicillin-resistant Staphylococcus aureus bacteremia before switching therapy

Clinical Infectious Diseases

Volumn 59, Issue 10, 2014, Pages 1455-1461

  Kullar, Ravina ^a   McKinnell, James A ^b,c   Sakoulas, George ^d  

^a CUBIST PHARMACEUTICALS INC   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Memorial Medical Center   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Daptomycin; MRSA bacteremia; Persistent bacteremia; Rapid diagnostics; Vancomycin

Indexed keywords

BETA LACTAM ANTIBIOTIC; BIOLOGICAL MARKER; CEFTAROLINE; DAPTOMYCIN; ERTAPENEM; GENTAMICIN; INTERLEUKIN 10; INTERLEUKIN 1BETA; LINEZOLID; POLYPEPTIDE ANTIBIOTIC AGENT; RIFAMPICIN; VANCOMYCIN; ANTIINFECTIVE AGENT;

ALTERNATIVE MEDICINE; ARTICLE; BACTERIAL CLEARANCE; DEVICE INFECTION; DISEASE DURATION; DRUG TREATMENT FAILURE; ENDOCARDITIS; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPECTATION; HUMAN; INFECTION RISK; INNATE IMMUNITY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR DIAGNOSTICS; MOLECULAR TYPING; MORTALITY; NONHUMAN; OSTEOMYELITIS; PHENOTYPE; POLYMERASE CHAIN REACTION; PRACTICE GUIDELINE; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; SALVAGE THERAPY; SOFT TISSUE INFECTION; STAPHYLOCOCCAL BACTEREMIA; SURFACE CHARGE; ANIMAL; BACTEREMIA; COMPLICATION; DRUG COMBINATION; DRUG EFFECTS; DRUG SUBSTITUTION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIOLOGY; STAPHYLOCOCCAL INFECTIONS; TIME; TREATMENT FAILURE; TREATMENT OUTCOME;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTEREMIA; BIOLOGICAL MARKERS; DRUG SUBSTITUTION; DRUG THERAPY, COMBINATION; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCAL INFECTIONS; TIME FACTORS; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 84908291974     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciu583     Document Type: Article

References (39)

1. Hawkins C, Huang J, Jin N, et al. Persistent Staphylococcus aureus bacteremia: an analysis of risk factors and outcomes. Arch Intern Med 2007;167:1861-7.
2. Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillinresistant Staphylococcus aureus infections in adults and children: executive summary. Clin Infect Dis 2011;52:285-92.
3. Levine DP, Fromm BS, Reddy BR. Slow response to vancomycin or vancomycin plus rifampin in methicillin-resistant Staphylococcus aureus endocarditis. Ann Intern Med 1991;115:674-80.
4. Sakoulas G, Eliopoulos GM, Fowler VG Jr, et al. Reduced susceptibility of Staphylococcus aureus to vancomycin and platelet microbicidal protein correlates with defective autolysis and loss of accessory gene regulator (agr) function. Antimicrob Agents Chemother 2005;49:2687-92.
5. Khatib R, Johnson LB, Fakih MG, et al. Persistence in Staphylococcus aureus bacteremia: incidence, characteristics of patients and outcome. Scand J Infect Dis 2006;38:7-14.
6. Ok HS, Lee HS, Park MJ, et al. Predictors and clinical outcomes of persistent methicillin-resistant Staphylococcus aureus bacteremia: a prospective observational study. Korean J Intern Med 2013;28:678-86.
7. Welsh KJ, Skrobarcek KA, Abbott AN, et al. Predictors of relapse of methicillin-resistant Staphylococcus aureus bacteremia after treatment with vancomycin. J Clin Microbiol 2011;49:3669-72.
8. Rose WE, Eickhoff JC, Shukla SK, et al. Elevated serum interleukin-10 at time of hospital admission is predictive of mortality in patients with Staphylococcus aureus bacteremia. J Infect Dis 2012;206:1604-11.
9. Nizet V. Antimicrobial peptide resistance mechanisms of human bacterial pathogens. Curr Issues Mol Biol 2006;8:11-26.
10. Mishra NN, McKinnell J, Yeaman MR, et al. In vitro cross-resistance to daptomycin and host defense cationic antimicrobial peptides in clinical methicillin-resistant Staphylococcus aureus isolates. Antimicrob Agents Chemother 2011;55:4012-8.
11. Azmi S, Srivastava S, Mishra NN, et al. Characterization of antimicrobial, cytotoxic, and antiendotoxin properties of short peptides with different hydrophobic amino acids at "a" and "d" positions of a heptad repeat sequence. J Med Chem 2013;56:924-39.
12. Kumar A, Roberts D, Wood KE, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006;34:1589-96.
13. Lodise TP, McKinnon PS, Swiderski L, et al. Outcomes analysis of delayed antibiotic treatment for hospital-acquired Staphylococcus aureus bacteremia. Clin Infect Dis 2003;36:1418-23.
14. Bauer KA, West JE, Balada-Llasat JM, et al. An antimicrobial stewardship program's impact with rapid polymerase chain reaction methicillinresistant Staphylococcus aureus/S. aureus blood culture test in patients with S. aureus bacteremia. Clin Infect Dis 2010;51:1074-80.
15. Huang AM, Newton D, Kunapuli A, et al. Impact of rapid organism identification via matrix-assisted laser desorption/ionization timeofflight combined with antimicrobial stewardship team intervention in adult patients with bacteremia and candidemia. Clin Infect Dis 2013;57:1237-45.
16. Fowler VG Jr, Sanders LL, Sexton DJ, et al. Outcome of Staphylococcus aureus bacteremia according to compliance with recommendations of infectious diseases specialists: experience with 244 patients. Clin Infect Dis 1998;27:478-86.
17. Yoon YK, Kim JY, Park DW, et al. Predictors of persistent methicillinresistant Staphylococcus aureus bacteraemia in patients treated with vancomycin. J Antimicrob Chemother 2010;65:1015-8.
18. Murray KP, Zhao JJ, Davis SL, et al. Early use of daptomycin versus vancomycin for methicillin-resistant Staphylococcus aureus bacteremia with vancomycin minimum inhibitory concentration >1 mg/L: a matched cohort study. Clin Infect Dis 2013;56:1562-9.
19. Kullar R, Davis SL, Kaye KS, et al. Implementation of an antimicrobial stewardship pathway with daptomycin for optimal treatment of methicillinresistant Staphylococcus aureus bacteremia. Pharmacotherapy 2013;33:3-10.
20. Moore CL, Osaki-Kiyan P, Haque NZ, et al. Daptomycin versus vancomycin for bloodstream infections due to methicillin-resistant Staphylococcus aureus with a high vancomycin minimum inhibitory concentration: a case-control study. Clin Infect Dis 2012;54:51-8.
21. McDaneld PM, Spooner LM, Mohr JF, et al. Use of daptomycin to treat infections with methicillin-resistant Staphylococcus aureus isolates having vancomycin minimum inhibitory concentrations of 1. 5 to 2 μg/mL. Ann Pharmacother 2013;47:1654-65.
22. Jang HC, Kim SH, Kim KH, et al. Salvage treatment for persistent methicillinresistant Staphylococcus aureus bacteremia: efficacy of linezolid with or without carbapenem. Clin Infect Dis 2009;49:395-401.
23. Deresinski S. Vancomycin in combination with other antibiotics for the treatment of serious methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis 2009;49:1072-9.
24. Bayer AS, Schneider T, Sahl HG. Mechanisms of daptomycin resistance in Staphylococcus aureus: role of the cell membrane and cell wall. Ann N Y Acad Sci 2013;1277:139-58.
25. Saleh-Mghir A, Muller-Serieys C, Dinh A, et al. Adjunctive rifampin is crucial to optimizing daptomycin efficacy against rabbit prosthetic joint infection due to methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2011;55:4589-93.
26. Cirioni O, Mocchegiani F, Ghiselli R, et al. Daptomycin and rifampin alone and in combination prevent vascular graft biofilm formation and emergence of antibiotic resistance in a subcutaneous rat pouch model of staphylococcal infection. Eur J Vasc Endovasc Surg 2010;40:817-22.
27. Lefebvre M, Jacqueline C, Amador G, et al. Efficacy of daptomycin combined with rifampicin for the treatment of experimental methicillin-resistant Staphylococcus aureus (MRSA) acute osteomyelitis. Int J Antimicrob Agents 2010;36:542-4.
28. Sakoulas G, Eliopoulos GM, Alder J, et al. Efficacy of daptomycin in experimental endocarditis due to methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2003;47:1714-8.
29. Dhand A, Bayer AS, Pogliano J, et al. Use of antistaphylococcal beta-lactams to increase daptomycin activity in eradicating persistent bacteremia due to methicillin-resistant Staphylococcus aureus: role of enhanced daptomycin binding. Clin Infect Dis 2011;53:158-63.
30. Berti AD, Sakoulas G, Nizet V, et al. beta-Lactam antibiotics targeting PBP1 selectively enhance daptomycin activity against methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2013;57:5005-12.
31. Moise PA, Amodio-Groton M, Rashid M, et al. Multicenter evaluation of the clinical outcomes of daptomycin with and without concomitant beta-lactams in patients with Staphylococcus aureus bacteremia and mild to moderate renal impairment. Antimicrob Agents Chemother 2013;57:1192-200.
32. Sakoulas G, Okumura CY, Thienphrapa W, et al. Nafcillin enhances innate immune-mediated killing of methicillin-resistant Staphylococcus aureus. J Mol Med (Berl) 2014;92:139-49.
33. Fowler VG Jr, Boucher HW, Corey GR, et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 2006;355:653-65.
34. Friedland HD, O'Neal T, Biek D, et al. CANVAS 1 and 2: analysis of clinical response at day 3 in two phase 3 trials of ceftaroline fosamil versus vancomycin plus aztreonam in treatment of acute bacterial skin and skin structure infections. Antimicrob Agents Chemother 2012;56:2231-6.
35. Casapao AM, Davis SL, Barr VO, et al. A large retrospective evaluation of the effectiveness and safety of ceftaroline fosamil therapy. Antimicrob Agents Chemother 2014;58:2541-6.
36. Steed ME, Rybak MJ. Ceftaroline: a new cephalosporin with activity against resistant gram-positive pathogens. Pharmacotherapy 2010;30:375-89.
37. Lin JC, Aung G, Thomas A, et al. The use of ceftaroline fosamil in methicillinresistant Staphylococcus aureus endocarditis and deep-seated MRSA infections: a retrospective case series of 10 patients. J Infect Chemother 2013;19:42-9.
38. Rose WE, Schulz LT, Andes D, et al. Addition of ceftaroline to daptomycin after emergence of daptomycin-nonsusceptible Staphylococcus aureus during therapy improves antibacterial activity. Antimicrob Agents Chemother 2012;56:5296-302.
39. Sakoulas G, Moise PA, Casapao AM, et al. Antimicrobial salvage therapy for persistent staphylococcal bacteremia using daptomycin plus ceftaroline. Clin Ther 2014; doi:10.1016/j.clinthera.2014.05.061.